Driving down drug prices: how regulators can influence affordability

2017-05-03 In recent years there has been increasing global concern over drug prices and their affordability. And what is the role played by regulators in drug… Read More »

EMA adopts new guidance on monitoring of biologicals

2017-04-28 The European Medicines Agency (EMA) announced on 15 August 2016 that it had introduced a new guideline on the monitoring of biologicals, including biosimilars. The… Read More »

Sandoz plans to launch five more biosimilars by 2020

2017-04-26 Sandoz, the generics division of Novartis, has announced plans for five major global biosimilar launches by 2020. The company says that five biosimilar launches are… Read More »

The satisfaction of healthcare payers, patients and physicians with generic imatinib

2017-04-24 With the begining of the era of tyrosine kinase inhibitors (TKIs), chronic myeloid leukaemia (CML) became a chronic disease, in which good responding patients usually… Read More »

Pure red cell aplasia in a CKD patient after treatment with epoetin zeta

2017-04-21 Authors from the Versilia and Manzoni Hospitals in Italy report the case of a patient who developed pure red cell aplasia (PRCA) following subcutaneous administration… Read More »

Ways to reduce drug costs in Australia

2017-04-19 Drug costs in Australia are increasing at an alarming rate. This is driven mainly by expensive biological therapies, antiviral therapies for HIV and hepatitis C… Read More »

Doctors want more details in biosimilars labelling

2017-04-12 In the European Union (EU), labels (Summaries of Product Characteristics, SmPCs) for biosimilars and their reference products are, in many instances, almost identical despite different… Read More »

AES position statement on substitution of generic anti-epileptics

2017-04-12 A paper by the American Epilepsy Society (AES) discusses how the society’s position on generics substitution of anti-epileptic drugs has changed according to the results… Read More »

Biosimilar rituximab in biological naïve rheumatoid arthritis patients

2017-04-10 Cost remains a major constraint in the use of originator biologicals in rheumatology in developing countries, paving the way for ever increasing usage of biosimilars.… Read More »

Reasons for the success of a generics company in the Sudan market

2017-04-07 An exploratory, qualitative study carried out by colleagues from the University of Khartoum (Sudan) and Abertay University (UK) examined the reasons behind the success of… Read More »

Page 1 of 49 1 2 3 4 5 Next »... 49
Go Back Print